Provided by Tiger Trade Technology Pte. Ltd.

Humacyte, Inc.

0.5748
-0.0042-0.73%
Volume:1.53M
Turnover:871.73K
Market Cap:159.79M
PE:-1.16
High:0.5800
Open:0.5800
Low:0.5600
Close:0.5790
52wk High:2.55
52wk Low:0.5261
Shares:278.00M
Float Shares:245.00M
Volume Ratio:0.70
T/O Rate:0.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4975
EPS(LYR):-0.2582
ROE:-547.87%
ROA:-49.87%
PB:5.11
PE(LYR):-2.23

Loading ...

Humacyte Says Israeli Health Ministry Accepts Marketing Authorization Application for Symvess

MT Newswires Live
·
Apr 21

Humacyte Announces Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess® for Vascular Trauma Repair

THOMSON REUTERS
·
Apr 21

Humacyte: Ministry of Health Has Set 180-Working-Day Review Period for Maa Due to Existing FDA Approval of Symvess in Extremity Vascular Trauma

THOMSON REUTERS
·
Apr 21

Humacyte says Israel accepts Symvess marketing application, sets 180-day review period

Reuters
·
Apr 21

Humacyte announces annual shareholder meeting

Reuters
·
Apr 18

Humacyte Is Maintained at Overweight by Barclays

Dow Jones
·
Apr 08

Humacyte Inc. : Barclays Cuts Target Price to $1.5 From $3.5

THOMSON REUTERS
·
Apr 08

Largest borrow rate increases among liquid names

TIPRANKS
·
Apr 07

Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX) and Humacyte (HUMA)

TIPRANKS
·
Apr 02

Humacyte Cut to Speculative Buy From Buy by Benchmark

Dow Jones
·
Mar 31

Humacyte downgraded to Speculative Buy from Buy at Benchmark

TIPRANKS
·
Mar 31

Humacyte Inc : Benchmark Cuts to Speculative Buy From Buy; Cuts Target Price to $1 From $10

THOMSON REUTERS
·
Mar 31

Benchmark Downgrades Humacyte to Speculative Buy From Buy, Adjusts Price Target to $1 From $11

MT Newswires Live
·
Mar 31

Humacyte Is Maintained at Neutral by Piper Sandler

Dow Jones
·
Mar 31

Humacyte price target lowered to $1 from $3 at Piper Sandler

TIPRANKS
·
Mar 30

Humacyte Is Maintained at Buy by BTIG

Dow Jones
·
Mar 27

Humacyte Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 27

Humacyte posts bigger-than-expected Q4 loss

Reuters
·
Mar 27

Humacyte FY2025 net loss narrows to $40.8 million; revenue rises to $2.0 million

Reuters
·
Mar 27

Humacyte Q4 EPS $(0.13), Inline, Sales $467.000K Miss $1.343M Estimate

Benzinga Earnings
·
Mar 27